Gilead's remdesivir cut mortality risk 62% in COVID-19 study [Seeking Alpha]
Morgan Stanley (MS)
Last morgan stanley earnings: 4/16 07:15 am
Check Earnings Report
US:NYSE Investor Relations:
morganstanley.com/about-us-ir
Company Research
Source: Seeking Alpha
Healthcare|On the MoveGilead's remdesivir cut mortality risk 62% in COVID-19 studyJul. 10, 2020 9:08 AM ETGilead Sciences, Inc. (GILD)Douglas W. HouseGilead Sciences (NASDAQ:additional dataPhase 3 SIMPLE-Severe studyTreatment with remdesivir was associated with a 62% reduction in mortality compared to standard-of-care (SOC) treatment. 74.4% of treated patients recovered by day 14 versus 59.0% of those receiving SOC. Remdesivir demonstrated its superiority to SOC in terms of mortality rate, 7.6% at day 14 versus 12.5% in patients not receiving the antiviral.The study assessed five-day and 10-day dosing regimens of remdesivir administered intravenously.Patients who received hydroxychloroquine in addition to remdesivir experienced lower recovery rates (57% vs. 69%) compared to those who received remdesivir without the malaria drug. Concomitant use of hydroxychloroquine was not associated with a higher mortality rate in the 14 day analysis window.Results from its remdesivir compassionate
Show less
Read more
Impact Snapshot
Event Time:
MS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MS alerts
High impacting Morgan Stanley news events
Weekly update
A roundup of the hottest topics
MS
News
- Netflix (NFLX) Q1 2024 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
- ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Morgan Stanley Investors to Inquire About Securities Class Action Investigation – MSGlobeNewswire
- Superfeet Announces New Campaign Supporting Track & Field Athletes Ahead of 2024 Olympics & Paralympics [Yahoo! Finance]Yahoo! Finance
- Nordstrom forms special committee to evaluate family takeover interest [Seeking Alpha]Seeking Alpha
- Morgan Stanley Wealth Management Pulse Survey Reveals Bullish Sentiment Despite Drop in OptimismBusiness Wire
MS
Earnings
- 4/16/24 - Beat
MS
Sec Filings
- 4/18/24 - Form 424B2
- 4/18/24 - Form FWP
- 4/18/24 - Form 144
- MS's page on the SEC website